Bassand J P, Cassagnes J, Machecourt J, Anguenot T, Lusson J R, Borel E, Schiele F, Wolf J F, Vachet D
Service de cardiologie, hôpital universitaire Saint-Jacques, Besançon.
Arch Mal Coeur Vaiss. 1990 Feb;83 Spec No 1:31-6.
The early intravenous administration of thrombolytic agents in the acute phase of myocardial infarction induces reperfusion of the artery responsible for the necrosis, thereby limiting the size of the infarct and preserving the left ventricular systolic function with consequent reduction of short- or long-term mortality. With the exception of urokinase, these effects have been demonstrated with all thrombolytic agents used so far, including streptokinase, plasminogen tissue activator and anistreplase. Owing to its special pharmacokinetic properties, the latest thrombolytic agent, formerly known as APSAC (anisoylated plasminogen streptokinase activator complex), provides a high arterial reperfusion rate with a low percentage of reocclusion. As a result, the mean size of the infarct is reduced by 31 per cent (36% in the case of anterior infarct), and the left ventricular systolic function is highly significantly preserved.
在心肌梗死急性期尽早静脉注射溶栓剂可促使造成坏死的动脉再灌注，从而限制梗死面积，保留左心室收缩功能，进而降低短期或长期死亡率。除尿激酶外，迄今使用的所有溶栓剂（包括链激酶、组织型纤溶酶原激活剂和茴香酰化纤溶酶原链激酶激活剂复合物）均已证实有上述作用。由于其特殊的药代动力学特性，最新的溶栓剂（原称为APSAC）可提供较高的动脉再灌注率，再闭塞率较低。结果，梗死平均面积缩小31%（前壁梗死时为36%），左心室收缩功能得到高度显著保留。
